Company / Shareholders' Equity
Phathom Pharmaceuticals, Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$438.2M
FY2025
5-year range
-$438.2M / $72.2M
FY2021-FY2025
Trend
-502.2%
vs FY2024
Sector context
#207 of 213
Health Care
What the data says
Phathom Pharmaceuticals, Inc. reports negative total equity of -$438M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$438M in FY2025.
Declined from -$73M to -$438M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 213This company -$438.2M Sector average $2.5B
▼
-117.2% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity decreased 502.2% year-over-year.
- Ranks #207 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -6.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$438.2M | -502.2% |
| FY2024 | -$72.8M | +0.0% |
| FY2023 | -$72.8M | +2.7% |
| FY2022 | -$74.8M | -203.7% |
| FY2021 | $72.2M | -62.9% |
| FY2020 | $194.3M | -14.8% |
| FY2019 | $228.0M | +17825.9% |
| FY2018 | -$1.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026